Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ESMO 2020 | The SECOMBIT trial: the first results

In which sequence does targeted and immuno therapy performs best in patients with metastatic melanoma? This question comes up almost daily in clinical practice. The phase II SECOMBIT trial might plant the seed that will give the answer in the nearby future. Professor Paolo Ascierto will bring you the results of this exciting study.

Click here to find the rest of our ESMO 2020 coverage.

  • Sponsors

    This program is editorially independent and is financially supported by: